# Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients

> **NCT00117507** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Iron Overload

## Interventions

- **DRUG:** Deferasirox

## Key facts

- **NCT ID:** NCT00117507
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2021-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00117507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00117507, "Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00117507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*